The International Collaboration on Cosmetics Safety (ICCS) has elected its 2026 board officers reflecting its continued commitment to advancing approaches in animal-free cosmetics safety.
L’Oreal global head of human and environmental safety evaluation Stéphane Dhalluin has been re-elected as chair; Cosmetics Alliance Canada CEO Darren Praznik is vice-chair; Procter & Gamble safety advocacy and regulatory toxicology director Heike Scheffler is secretary; while Kenvue head of global toxicology and clinical safety Michael Southall remains treasurer.
The ICCS said it is now well positioned to deepen collaboration and advance its mission at a pivotal time for cosmetics safety science worldwide.
“I am thrilled to continue working with an outstanding group of officers whose leadership and dedication are essential to advancing the ICCS mission,” said President and CEO Erin Hill.
“As the scientific and regulatory landscape continues to evolve, this Board brings the experience, perspective, and collaborative spirit needed to accelerate progress toward global adoption of animal-free safety science.”
ICCS was formed in early 2023 with the mission to advance the adoption of animal-free assessments of cosmetics, and their ingredients, for human and environmental safety.
The organization is comprised from market leaders in the cosmetic product and ingredient manufacturers sector, notable trade and research associations, and influential animal protection organizations.
Current ingredient manufacturer members include BASF, Croda, Evonik and Inolex.
In 2025, ICCS delivered tangible scientific and regulatory progress, including the release of a Best Practice Guidance document, the development of new methodologies supporting next generation risk assessment, and extensive engagement with regulators and scientists worldwide.
These efforts strengthened global dialogue around animal-free safety science and helped advance shared understanding of how innovative, animal-free approaches can support regulatory decision-making.
“Building on the momentum of a highly impactful 2025—a year defined by robust achievements and the delivery of concrete scientific frameworks—our mission is clearer than ever,” said Dhalluin.
“By leveraging our unique global, multi-stakeholder collaboration, we remain dedicated to bridging the gap between innovation and regulation,” he added.
“Together, we are ensuring that cutting-edge, animal-free science becomes the universal standard for protecting human and environmental health.”
